Karam, MohammadAlsaif, AbdulmalikAl-Naseem, AbdulrahmanHayre, AmritAl Jabbouri, AbdurrahmanAldubaikhi, AhmedKahlar, NarvairAl-Mutairi, Salem2023-06-152023-06-152022-04Karam, M., Alsaif, A., Al-Naseem, A., Hayre, A., Al Jabbouri, A., Aldubaikhi, A., Kahlar, N., & Al-Mutairi, S. (2023). Mycophenolate versus Methotrexate in Non-infectious Ocular Inflammatory Disease: A Systematic Review and Meta-Analysis. Ocular immunology and inflammation, 31(3), 613–620.0927-39481744-507810.1080/09273948.2022.203416635201968http://hdl.handle.net/20.500.14200/978Purpose: To compare the outcomes of mycophenolate mofetil (MMF) versus methotrexate (MTX) in non-infectious ocular inflammatory disease (NIOID). Methods: The study was performed as per the PRISMA Guidelines. A search identified all studies comparing MMF versus MTX in NIOID. Treatment result and side effects were primary outcomes. Results: Four studies enrolling 905 patients were identified. There was no significant difference between MMF and MTX groups in overall treatment success (OR = 0.97, P = .96), treatment failure (OR = 0.86, P = .85). MTX showed a significantly improved effect in cases involving posterior uveitis and panuveitis (OR = 0.41, P = .003). In addition, MTX was associated with a faster median time to treatment success and had less side effects when compared to MTX, however this was not significant. For secondary outcomes, no significant difference was found in visual acuity and resolution of macular oedema. Conclusion: MMF is comparable to MTX in the treatment of NIOID.enOphthalmologySurgeryArticle